“Human Genome Sciences and GlaxoSmithKline PLC announced that BENLYSTA (belimumab, formerly LymphoStat-B) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that belimumab plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.” Human Genome Sciences,Inc. (quote:HGSI) stock rose more than 200% this morning on this news.
Posted by: Will | July 20, 2009